Description: GlycoNex Incorporation develops cancer drugs using glycosphingolipid antigen and human monoclonal antibody technologies in Taiwan. Its technology platform enables glycan-directed cancer therapy and analytical tools for glycosylation. The company develops GNX102, a humanized antibody for cancer; and GNX201, GNX202, GNX203, and GNX204 for various solid tumors. It also develops Denosumab, a humanized IgG2 antibody that is in preclinical stage for the treatment of osteoporosis and oncology; and Aflibercept, a vascular endothelial growth factor binding fusion protein for the treatment of ophthalmology and oncology. GlycoNex Incorporation was founded in 2001 and is based in New Taipei City, Taiwan.
Home Page: www.glyconex.com.tw
No. 97, Xintai 5th Road
New Taipei City,
221
Taiwan
Phone:
886 2 2697 4168
Officers
| Name | Title |
|---|---|
| Dr. Mei-Chun Yang | Pres, CEO & Mang. |
| Ti-Fen Wu | Chief Financial Officer & Accounting Supervisor |
| Yaohua Lu | VP of Admin. |
| Dr. Sen-Itiroh Hakomori M.D., Ph.D. | Principal Consultant |
Exchange: TWO
Country: TW
Currency: New Taiwan Dollar (NT$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.3731 |
| Price-to-Sales TTM: | 111.0793 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |